Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Objectives Despite national recommendations for use ofpneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasivepneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugatevaccines (PCVs) with expanded coverage have the potential to reduce thepneumococcal diseas...

Full description

Bibliographic Details
Main Authors: Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff, Christian Theilacker
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Expert Review of Vaccines
Subjects:
pneumococcal conjugate vaccine
cost-effectiveness
pneumococcal disease
germany
community acquired pneumonia
Online Access:http://dx.doi.org/10.1080/14760584.2023.2262575

Internet

http://dx.doi.org/10.1080/14760584.2023.2262575

Similar Items